|
Aug 29
|
Kane Biotech Announces Second Quarter 2024 Financial Results
|
|
Aug 29
|
Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations
|
|
Aug 28
|
Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel
|
|
Jul 23
|
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
|
|
Jul 17
|
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
|
|
Jun 27
|
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
|
|
Jun 25
|
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
|
|
Apr 11
|
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
|
|
Dec 29
|
Kane Biotech Announces Correction to Press Release
|
|
Dec 28
|
Kane Biotech Announces Amendment to its Credit Facility
|
|
Dec 20
|
Kane Biotech Receives Offer for its Interest in STEM Animal Health
|
|
Nov 28
|
Kane Biotech Announces Improved Third Quarter 2023 Financial Results
|
|
Jun 23
|
Kane Biotech Announces Issuance of Restricted Share Units
|
|
May 25
|
Kane Biotech Announces First Quarter 2023 Financial Results
|
|
May 25
|
Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
|
|
May 18
|
Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow
|